The advent of many novel therapies for the treatment of T2DM increases the choice of drugs used as a second-line treatment. The sodium-glucose co-transporter 2 (SGLT2) inhibitors have been known to act by stimulating glucose excretion in the urine and is the most recent class of therapy that has been approved for T2DM management [7]. The gene discussed is SLC5A2; the disease is type 2 diabetes mellitus.